Results showed that Losartan (300 μM) decreased CT-26 cells migration (Figure 4B(Fig. 4)) and inhibited the enzymatic activities of MMP-2 and -9, key metastatic enzymes in CRC cells (Figure 4C(Fig. 4)). The gene discussed is MMP2; the disease is colorectal carcinoma.